GLP-1 Drugs: A Surging Sector Exceeding Global Markets

Over the past five years, GLP-1 drugs for weight management have seen unprecedented growth, outperforming the performance of traditional pharmaceuticals and even broader markets like the S&P 500. This surge in returns has been attributed to the burgeoning success of diabetes treatments like Ozempic by Novo Nordisk, which have redefined expectations within healthcare. A recent analysis from eToro revealed that the GLP-1 drug producers’ basket saw a 130% increase in value, while other pharmaceutical companies only managed an average gain of 42%, highlighting the sector’s potential.